Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Novartis Lotensin

  • News

Executive Summary

Professional Detailing, Inc. gains U.S. marketing rights for the ACE inhibitor benazepril and Lotensin HCT (benazepril/hydrochlorothiazide) through 2003. PDI will also co-promote Lotrel (amlodipine/benazepril). Novartis will continue to manufacture the three products

You may also be interested in...



PDI Identifies 40 Potential Products For Sales Through LifeCycle X-Tension

Professional Detailing, Inc. has identified 40 products that could be marketed through its LifeCycle X-Tension service, CEO Charles Saldarini said.

PDI Identifies 40 Potential Products For Sales Through LifeCycle X-Tension

Professional Detailing, Inc. has identified 40 products that could be marketed through its LifeCycle X-Tension service, CEO Charles Saldarini said.

Novartis Starlix/Diovan Combo Trial In Diabetes Planned For Fourth Quarter

Novartis hopes to begin a study of Starlix and Diovan used in combination for the prevention of type 2 diabetes before year-end.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS037921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By